FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2344716011> ?p ?o ?g. }

• W2344716011 endingPage "37" @default.
• W2344716011 startingPage "30" @default.
• W2344716011 abstract "To determine the impact of elevated neuroendocrine serum markers on treatment outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing treatment with abiraterone in a post-chemotherapy setting.Chromogranin A (CGa) and neurone-specific enolase (NSE) were determined in serum drawn before treatment with abiraterone from 45 patients with mCRPC. Outcome measures were overall survival (OS), prostate-specific antigen (PSA) response defined by a PSA level decline of ≥50%, PSA progression-free survival (PSA-PFS), and clinical or radiographic PFS.The CGa and NSE serum levels did not correlate (P = 0.6). Patients were stratified in to low- (nine patients), intermediate- (18) or high-risk (18) groups according to elevation of none, one, or both neuroendocrine markers, respectively. The risk groups correlated with decreasing median OS (median OS not reached vs 15.3 vs 6.6 months; P < 0.001), decreasing median clinical or radiographic PFS (8.3 vs 4.4 vs 2.7 months; P = 0.001) and decreasing median PSA-PFS (12.0 vs 3.2 vs 2.7 months; P = 0.012). In multivariate Cox regression analysis the combination of CGa and NSE (≥1 marker positive vs both markers negative) remained significant predictors of OS, clinical or radiographic PFS, and PSA-PFS. We did not observe a correlation with PSA response (63% vs 35% vs 31%; P = 0.2).Chromogranin A and NSE did not predict PSA response in patients with mCRPC treated with abiraterone. However, we observed a correlation with shorter PSA-PFS, clinical or radiographic PFS, and OS. This might be due to an elevated risk of developing resistance under abiraterone treatment related to neuroendocrine differentiation." @default.
• W2344716011 created "2016-06-24" @default.
• W2344716011 creator A5002762582 @default.
• W2344716011 creator A5003688542 @default.
• W2344716011 creator A5010135926 @default.
• W2344716011 creator A5022045745 @default.
• W2344716011 creator A5024163450 @default.
• W2344716011 creator A5030908792 @default.
• W2344716011 creator A5038906134 @default.
• W2344716011 creator A5039792880 @default.
• W2344716011 creator A5050614784 @default.
• W2344716011 creator A5053604427 @default.
• W2344716011 creator A5059770908 @default.
• W2344716011 creator A5063830479 @default.
• W2344716011 creator A5067456208 @default.
• W2344716011 creator A5089218170 @default.
• W2344716011 date "2016-04-27" @default.
• W2344716011 modified "2023-10-10" @default.
• W2344716011 title "Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy" @default.
• W2344716011 cites W123190302 @default.
• W2344716011 cites W1898749913 @default.
• W2344716011 cites W1975356306 @default.
• W2344716011 cites W2006027491 @default.
• W2344716011 cites W2013954728 @default.
• W2344716011 cites W2034235423 @default.
• W2344716011 cites W2047925700 @default.
• W2344716011 cites W2077039324 @default.
• W2344716011 cites W2080140117 @default.
• W2344716011 cites W2083792977 @default.
• W2344716011 cites W2083981959 @default.
• W2344716011 cites W2097121410 @default.
• W2344716011 cites W2110534364 @default.
• W2344716011 cites W2121863482 @default.
• W2344716011 cites W2121953515 @default.
• W2344716011 cites W2137467802 @default.
• W2344716011 cites W2139855987 @default.
• W2344716011 cites W2148643283 @default.
• W2344716011 cites W2156923287 @default.
• W2344716011 cites W2166918329 @default.
• W2344716011 cites W2167331614 @default.
• W2344716011 cites W2168901797 @default.
• W2344716011 cites W3166582654 @default.
• W2344716011 doi "https://doi.org/10.1111/bju.13493" @default.
• W2344716011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27037533" @default.
• W2344716011 hasPublicationYear "2016" @default.
• W2344716011 type Work @default.
• W2344716011 sameAs 2344716011 @default.
• W2344716011 citedByCount "40" @default.
• W2344716011 countsByYear W23447160112016 @default.
• W2344716011 countsByYear W23447160112017 @default.
• W2344716011 countsByYear W23447160112018 @default.
• W2344716011 countsByYear W23447160112019 @default.
• W2344716011 countsByYear W23447160112020 @default.
• W2344716011 countsByYear W23447160112021 @default.
• W2344716011 countsByYear W23447160112022 @default.
• W2344716011 countsByYear W23447160112023 @default.
• W2344716011 crossrefType "journal-article" @default.
• W2344716011 hasAuthorship W2344716011A5002762582 @default.
• W2344716011 hasAuthorship W2344716011A5003688542 @default.
• W2344716011 hasAuthorship W2344716011A5010135926 @default.
• W2344716011 hasAuthorship W2344716011A5022045745 @default.
• W2344716011 hasAuthorship W2344716011A5024163450 @default.
• W2344716011 hasAuthorship W2344716011A5030908792 @default.
• W2344716011 hasAuthorship W2344716011A5038906134 @default.
• W2344716011 hasAuthorship W2344716011A5039792880 @default.
• W2344716011 hasAuthorship W2344716011A5050614784 @default.
• W2344716011 hasAuthorship W2344716011A5053604427 @default.
• W2344716011 hasAuthorship W2344716011A5059770908 @default.
• W2344716011 hasAuthorship W2344716011A5063830479 @default.
• W2344716011 hasAuthorship W2344716011A5067456208 @default.
• W2344716011 hasAuthorship W2344716011A5089218170 @default.
• W2344716011 hasBestOaLocation W23447160111 @default.
• W2344716011 hasConcept C121608353 @default.
• W2344716011 hasConcept C126322002 @default.
• W2344716011 hasConcept C126894567 @default.
• W2344716011 hasConcept C143998085 @default.
• W2344716011 hasConcept C204232928 @default.
• W2344716011 hasConcept C2780192828 @default.
• W2344716011 hasConcept C2781406297 @default.
• W2344716011 hasConcept C71924100 @default.
• W2344716011 hasConcept C77231918 @default.
• W2344716011 hasConcept C90924648 @default.
• W2344716011 hasConceptScore W2344716011C121608353 @default.
• W2344716011 hasConceptScore W2344716011C126322002 @default.
• W2344716011 hasConceptScore W2344716011C126894567 @default.
• W2344716011 hasConceptScore W2344716011C143998085 @default.
• W2344716011 hasConceptScore W2344716011C204232928 @default.
• W2344716011 hasConceptScore W2344716011C2780192828 @default.
• W2344716011 hasConceptScore W2344716011C2781406297 @default.
• W2344716011 hasConceptScore W2344716011C71924100 @default.
• W2344716011 hasConceptScore W2344716011C77231918 @default.
• W2344716011 hasConceptScore W2344716011C90924648 @default.
• W2344716011 hasIssue "1" @default.
• W2344716011 hasLocation W23447160111 @default.
• W2344716011 hasLocation W23447160112 @default.
• W2344716011 hasOpenAccess W2344716011 @default.
• W2344716011 hasPrimaryLocation W23447160111 @default.
• W2344716011 hasRelatedWork W189616576 @default.

• next